Optimizing Utilization of PSMA PET into a Urological Practice with Dr. Albala скачать в хорошем качестве

Optimizing Utilization of PSMA PET into a Urological Practice with Dr. Albala

David M. Albala, MD, Chief of Urology, Crouse Hospital, Syracuse, New York, discusses the integration of PSMA PET imaging into clinical practice. In this 16-minute presentation, Dr. Albala emphasizes the role of PSMA PET as a disruptive technology in prostate cancer management. PSMA PET demonstrates significantly higher sensitivity than conventional imaging, proving highly effective for identifying metastatic disease in patients with biochemical recurrence. Dr. Albala references studies that confirm PSMA PET's superiority for initial staging and its ability to detect high-risk features, particularly in larger nodes or higher PSA levels. Research highlights PSMA PET’s prognostic value, with higher uptake linked to poorer outcomes and stronger predictive accuracy than PSA alone. Dr. Albala stresses that practices seeking to implement PSMA PET programs must consider regulatory requirements, staffing, and logistics, with successful operations typically requiring at least 25 scans per month to break even. As PSMA PET continues to shape prostate cancer care, ongoing trials aim to refine its role in optimizing treatment decisions and improving patient outcomes.